撰文丨王聪 编辑丨王多鱼 排版丨水成文 胃肠道中表达的众多 G 蛋白偶联受体 （GPCR） 在激活后作为重要的转导器来调控多种生理功能。其中， TGR5 是一种在肠内分泌 L 细胞中表达的重要的胃肠道 GPCR，它能被肠道 胆汁酸 激活 ， 并促进 GLP- 1 分泌，从而在葡萄糖利用中发挥作用。 然而，TGR5 在体内多组织分布，长期补充外源 TGR5 激动剂会引发 肝胆毒性 ，这大大限制了 TGR5 激 动剂开发。 2025 年 11 月 19 日，中国科学院上海药物 研究 所 甘勇 、 周虎 团队 （ 张雅琪 、 黄蕙 、 汪雅莹 为论 文共同第一作者 ） 在 Science 子刊 Science Translational Medicine 上发表了题为： Intestinal TGR5- targeted Carrier-Drug Conjugate Improves Glycemic Control in Mice and Pigs 为题的研究论文。 该研究提出了一种全新的非吸收 型 载体-药物偶联物 （ CaDC ） 策略，能够在肠 腔侧持续 激活 TGR5 ，实现持续且安全的降血糖，效果超过了 ...

Domestic Investment - Zhizili Technology completed seed round financing of several million yuan, led by Cloud Angel Fund, focusing on a six-dimensional force sensing solution using self-developed machine learning algorithms and fiber grating sensing technology [1] - Xiyuan Anjian announced over 200 million yuan A round financing, led by Beijing Pharmaceutical Health Industry Investment Fund, to support the key III phase clinical research of its CGRP small molecule drug BR005 [2] - Fuxin Digital completed 50 million yuan Pre-A round financing, led by Yuan Yi Capital, to enhance its AI medical solutions and expand its team [3][4] - Jiayu Medical secured several million yuan angel round financing, led by Guokai Investment, to accelerate the registration and clinical promotion of its handheld magnetic particle imaging system [5] - Fengjia Technology and Xingwang Xintong received approval for their listings on the New Third Board, focusing on chip design and integrated communication solutions respectively [6][7] - Zhizhi Chip completed seed round financing of tens of millions of yuan, focusing on high-performance operator discovery and optimization [8] - Yuntu Zhixing raised tens of millions of dollars in angel round financing, focusing on geographic information and spatial intelligence computing [9] - Yuying Trade completed 8 million yuan angel round financing, focusing on software development and brand customization [10] - Nuowan Microelectronics completed nearly 100 million yuan angel round financing, focusing on optical interconnection chips [11] - Henan Hippo Technology completed 26 million yuan angel round financing, focusing on short video social e-commerce [12] - Anxin Medical completed a significant angel round financing to enhance its gynecological diagnostic tools [13] Foreign Investment - 1Mind AI raised $30 million in A round financing, focusing on AI sales service tools [14] - Scribe completed $75 million in C round financing, with a post-financing valuation of $1.3 billion, focusing on workflow management software [15] - Onchilles Pharma raised $25 million in A1 round financing, focusing on broad-spectrum cancer treatment candidates [16] - Majestic Labs secured $100 million in A round financing, focusing on AI infrastructure for high-memory AI servers [17] - Iambic Therapeutics received $100 million in strategic investment, focusing on AI-driven medical platforms [18] - Gamma completed $68 million in B round financing, achieving a valuation of $2.1 billion, focusing on AI-generated presentations [19] IPO Queue - Real Bio submitted an IPO application, focusing on innovative drug development for antiviral and oncology treatments [20] - Mindray Medical submitted an IPO application, focusing on medical device development across multiple fields [21] - Zhongding Intelligent submitted an IPO application, focusing on customized solutions for various industries [22]

Summary of Key Points from the Conference Call Company Overview - **Company**: 金财控股 (Jincai Holdings) - **Industry**: Biotechnology and AI for Science Core Business and Model - 金财控股 focuses on using AI and robotics to empower drug discovery and new materials, operating as a research and development service platform [2][7][9] - The company has over 300 global clients, including 17 of the top 20 multinational pharmaceutical companies, showcasing its industry-leading technology platform [2][8] Recent Developments - A significant collaboration with 礼来 (Eli Lilly) was established, valued at approximately $350 million, involving AI-enabled large molecule antibody drug development [3][17] - Two AI-developed molecules for hair growth have been registered as cosmetic ingredients in the U.S. and received FDA approval, indicating successful application of AI technology in consumer products [2][3] Financial Performance and Market Position - The company went public on June 13, 2024, becoming the first listed company in the specialized technology and AI for Science sector, with over 43% of shares held through the Hong Kong Stock Connect [2][6] - Major institutional investors, including Vanguard and BlackRock, have invested in the company, reflecting confidence in its long-term growth [2][6] Competitive Advantage - Unlike traditional Chinese pharmaceutical companies that transfer pipelines to large overseas firms after significant investment, 金财控股 shares R&D costs and outcomes with clients, ensuring stable long-term development [5][9] - The company’s unique fee structure covers the entire lifecycle of drug development, significantly shortening the R&D cycle from 4-6 years to approximately 2 years [9][11] AI and Robotics in Drug Development - AI enhances drug discovery by overcoming human experience limitations, allowing for multi-target and multi-property optimization, which significantly reduces time and costs while increasing success rates [10][11] - The 24/7 operation of robotic laboratories improves experimental efficiency and accumulates high-quality data for further AI training, creating a rapid iterative feedback loop [11][12] Market Potential and Future Outlook - The hair growth product developed showed an 80% effectiveness rate in a trial with 100 participants, indicating substantial market potential, as approximately 2.5 billion people globally suffer from hair loss [15] - The company anticipates maintaining a growth rate of 50-70% annually, excluding unexpected large orders [17] Impact of External Factors - The company is insulated from U.S.-China tensions as it focuses on preclinical research and does not handle sensitive clinical trial data [18] - The company has received recognition for its data capabilities, winning a national award for data elements, which is crucial for enhancing AI algorithms [19][23] Conclusion - 金财控股 is positioned as a leader in the biotechnology sector, leveraging AI and robotics to innovate drug discovery and development, with a robust business model that emphasizes collaboration and shared success with clients. The company's strategic partnerships and technological advancements suggest a promising future in both pharmaceutical and materials science markets.

Core Insights - Insilico Medicine aims to become the first globally to have an AI-enabled drug candidate enter Phase III clinical trials [2][4] - The company has developed a dual-engine business model focusing on both AI platform licensing and internal pipeline development [6] Company Overview - Insilico Medicine, founded in 2014, is a global AI-driven biotech company that utilizes its Pharma.AI platform for drug discovery and development [2] - The company has expanded the application of its AI technology to various sectors, including advanced materials, agriculture, nutrition products, and veterinary medicine [2] Pipeline and Clinical Progress - The core asset, Rentosertib (ISM001-055), is a first-in-class candidate for idiopathic pulmonary fibrosis (IPF) and has shown positive results in Phase IIa clinical trials in China [3] - The drug has received breakthrough therapy designation from the Center for Drug Evaluation (CDE) in China, which may expedite its clinical development and review process [3][4] - Insilico Medicine has generated over 20 clinical or IND-stage assets through its Pharma.AI platform, with three assets licensed to international pharmaceutical companies, totaling over $2 billion in contract value [4] Financial Performance - Revenue projections for Insilico Medicine from 2022 to 2024 are $30.15 million, $51.18 million, and $85.83 million, respectively, with gross margins increasing from 63.4% to 90.4% [5] - The net loss is expected to decrease significantly from $222 million in 2022 to $17.1 million in 2024 [5] Funding and Use of Proceeds - As of June 30, 2025, the company's cash and equivalents increased from approximately $126 million at the end of 2024 to about $213 million, primarily due to a Series E financing round [7] - The net proceeds from the IPO will be used for further clinical development of key pipeline candidates, development of new generative AI models, and expansion of automated laboratories [7]

Core Viewpoint - The article emphasizes the significant transformation in the global landscape driven by a new wave of technological revolution, highlighting the active role of small and medium-sized enterprises (SMEs) in China as they adapt and innovate within this context [1]. Group 1: Research Initiative - The "NEXT20" initiative aims to systematically track and research the growth potential of small and medium-sized listed companies in China's capital market, addressing the gap in growth research and evaluation for these firms [1]. - A total of 68 companies were selected from over 5,000 in the A-share market through a rigorous three-stage evaluation process, including data screening, quantitative scoring, and expert voting [3]. Group 2: Research Methodology - The research team conducted extensive field visits across various regions, focusing on sectors such as new materials, power equipment, and high-end manufacturing, as well as companies in the medical field with strong R&D capabilities [3]. - The research team utilized a multi-dimensional approach to assess companies, considering macroeconomic factors, industry trends, company fundamentals, and market sentiment, while also analyzing non-financial factors like technological barriers and supply chain management [5]. Group 3: Insights from Interviews - The project team discovered that SMEs demonstrated a keen insight into future trends and maintained a spirit of exploration, leveraging core technologies to develop new applications and expanding their business through mergers and acquisitions [6]. - Artificial intelligence emerged as a common focal point for these companies, with discussions highlighting its role in accelerating the development of new products and enhancing operational capabilities [6]. Group 4: Market Strategies - Many companies are pursuing overseas capacity expansion as a strategy to seek new growth opportunities and improve profitability, showing a rational approach to risk and reward [7]. - The project team has completed the company visits and will conduct in-depth research on the findings, with plans to unveil the "NEXT20" list in November, inviting various stakeholders to participate in a forum and award ceremony [7].

Core Insights - A new drug production technology developed by American researchers can synthesize a chiral molecule from glucose, potentially reducing the production costs of various prescription drugs significantly [1][2] - Chiral drugs are among the most expensive types of medications, with their high costs largely attributed to the expensive chiral building blocks required for synthesis [1] - The innovative process allows for the efficient production of (S)-3-hydroxy-gamma-butyrolactone (HBL), a key component in the synthesis of statins, antibiotics, and HIV inhibitors [1] Cost Reduction and Sustainability - The new method can lower production costs by over 60% compared to traditional petroleum-derived processes, while also reducing greenhouse gas emissions [1] - Glucose, which can be extracted from wood pulp and sawdust, provides a sustainable raw material for HBL production, opening new pathways for sustainable manufacturing [1] - The breakthrough in HBL production not only lowers costs for chiral drugs but also allows for the co-production of commercially valuable chemicals like glycolic acid, enhancing economic feasibility [2]

Core Insights - The "Shenzhen-Hong Kong-Guangzhou" innovation cluster has surpassed the "Tokyo-Yokohama" cluster to become the top global innovation cluster according to the World Intellectual Property Organization (WIPO) [1] - The inclusion of venture capital in the evaluation criteria reflects a more comprehensive understanding of the innovation ecosystem's vitality in the Greater Bay Area [1][2] - The cluster excels in three key dimensions: PCT international patent applications (2nd globally), scientific paper publications (3rd globally), and venture capital indicators (6th globally) [1] Group 1: Innovation Ecosystem - The new ranking methodology captures the true competitive strength of the region, highlighting the balanced activity of inventors, research output, and capital supply [2] - The region is forming a self-reinforcing system characterized by high-density coupling of innovation elements, leading to continuous generation of new knowledge and enterprises [4] - The integration of top-tier talent and resources in the cluster is facilitated by high-level platforms, dense university networks, and rich data resources [4] Group 2: Academic and Research Contributions - The influx of international scholars, such as Fields Medal winner Shing-Tung Yau, indicates a growing academic presence in the region [3] - Guangzhou's unique position as a hub for national laboratories and high-level research institutions enhances its research capabilities [4][5] - The concentration of universities and research institutes in Guangzhou plays a significant role in technology transfer and innovation [5] Group 3: Economic and Industrial Impact - The collaboration among Shenzhen, Hong Kong, and Guangzhou has created a robust innovation chain, enhancing the probability of successful commercialization [6] - The emergence of unicorns like DJI and Crystal Tech illustrates the effective integration of knowledge, resources, and capital in the region [7] - The Greater Bay Area's innovation ecosystem supports rapid prototyping and mass production across various industries, including AI and healthcare [8]

Core Insights - The event organized by the Ministry of Commerce's Investment Promotion Bureau aimed to facilitate exchanges between European life sciences and green technology companies and Wuxi High-tech Zone [1] - The Deputy Director expressed optimism about the industrial development in Wuxi High-tech Zone and emphasized the importance of building a collaborative platform for health innovation [1] - The Secretary of the Wuxi High-tech Zone expressed a desire to attract more quality enterprises and projects through the European window of the Investment Promotion Bureau [1] Industry and Company Engagement - Companies such as CS Pharmaceuticals, LightOx Biotechnology, Fine Treatment Medical Technology, and Aptamer Group engaged in targeted discussions with local enterprises [1] - The delegation visited the Wuxi High-tech Zone Exhibition Center and the AstraZeneca IoT Innovation Center, exploring potential project collaborations in drug research, medical devices, and health consumption [1] - The European representative office of the Investment Promotion Bureau aims to leverage its extensive network to introduce high-quality European projects to Chinese local parks, enhancing their openness to foreign investment [1]

Group 1 - The company achieved revenue of 227 million yuan in H1 2025, representing a growth of 16.58%, and a net profit attributable to shareholders of 50 million yuan, up 390.72% [1] - In Q2 alone, the company reported revenue of 120 million yuan, an increase of 37.71%, and a net profit attributable to shareholders of 22 million yuan, up 681.39% [1] - The overall gross margin for H1 2025 was 53.81%, an increase of 7.18 percentage points, and the net profit margin was 21.82%, up 17.05 percentage points, indicating a strong recovery in profitability [2] Group 2 - The DEL business segment continued to grow rapidly, with revenue of 102 million yuan in H1 2025, an increase of 40.45%, driven mainly by the growth of customized library services [2] - The company is advancing in new drug discovery and optimization through its DEL+AI/ML projects, achieving significant milestones in model and data development, high-throughput chemical platforms, and project pipelines [3] - The company has initiated two self-developed projects based on the HAILO platform, which have entered the evaluation stage for lead compounds [3] Group 3 - Revenue projections for the company from 2025 to 2027 are estimated at 507 million yuan, 609 million yuan, and 735 million yuan, with year-on-year growth rates of 18.83%, 20.10%, and 20.65% respectively [4] - The net profit attributable to shareholders is expected to be 78 million yuan, 111 million yuan, and 136 million yuan for the same period, with growth rates of 52.32%, 41.88%, and 22.47% respectively [4]

Group 1: Company Performance - Jiangsu's 713 A-share listed companies achieved a total revenue of over 1.68 trillion yuan and a net profit of nearly 148.2 billion yuan in the first half of 2025, with 429 companies reporting revenue growth [1] - 573 companies reported profitability, with 193 companies having a net profit exceeding 100 million yuan [1] - Over 40% of companies reported revenue exceeding 1 billion yuan, and 45 companies had revenue growth exceeding 50% [1] Group 2: AI Integration - More than half of the listed companies in Jiangsu mentioned "AI" or "artificial intelligence" in their semi-annual reports, indicating deep integration of AI tools with core business operations [2] - AI is reshaping drug development processes, as seen in Heng Rui Medicine's use of AI for early development strategies, enhancing clinical conversion efficiency [2] - Traditional industries are also benefiting from AI, with companies like Taihu Snow combining human creativity with AI for product design and optimization [2] Group 3: Cost Reduction and Innovation - AI applications are leading to cost reduction and efficiency improvements across various industries, such as a 20% reduction in R&D costs and a 30% decrease in R&D cycles in the steel industry [3] - Companies like Jingyuan Environmental are utilizing AI to provide comprehensive intelligent services, promoting industry upgrades [3] - The focus of AI applications is shifting towards vertical industries, allowing companies to address specific industry pain points effectively [3][4] Group 4: Industry Self-Regulation and Quality Improvement - The "anti-involution" trend is gaining traction in industries like photovoltaics, steel, cement, and chemicals, with companies actively addressing industry challenges through self-regulation and strategic adjustments [5] - Companies are focusing on differentiated competition and green transformation to achieve sustainable competitive advantages [5][6] Group 5: Overseas Expansion - 440 listed companies in Jiangsu reported a total overseas revenue of 290.6 billion yuan, with many adjusting their overseas production strategies to enhance global market adaptability [8] - Companies like Zhongxin Bo are establishing multiple production bases globally to respond quickly to international delivery demands [8] - Tianhe Energy has expanded its global service network, enhancing its international operational capabilities [9] Group 6: Mid-Year Dividend Distribution - Over 120 A-share listed companies in Jiangsu have announced mid-year dividend plans, with total distributions exceeding 10 billion yuan, reflecting improved corporate profitability and investor return awareness [11][12] - Companies are increasingly adopting clear mid- to long-term dividend plans, with some committing to a cash dividend ratio of no less than 30% of net profit [12][13] - The rise in mid-year dividends is seen as a positive signal for market stability and investor confidence [13]